SWOG clinical trial number
S9619
Phase II Trial of Intraperitoneal Cisplatin and Intravenous and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian Cancer, Intergroup
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Phase II Trial of Intraperitoneal Cisplatin and Intravenous and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian Cancer, Intergroup
Activated
05/15/1996
Closed
05/15/1998
Publication Information Expand/Collapse
2003
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an Intergroup phase II trial
2002
Excellent 2-year survival in women with optimally-debulked ovarian cancer treated with intraperitoneal and intravenous chemotherapy: a SWOG-ECOG-NCIC study (S9619)